beta

FTSV

Forty Seven Inc - Ordinary Shares

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-27-2019 after market close 03-27-2019 after market close 03-27-2019 after market close 03-27-2019 after market close 03-27-2019 after market close 03-27-2019 after market close 03-27-2019 after market close 11-13-2018 08-13-2018
Actual EPS -0.56 -0.56 -0.56 -0.56 -0.56 -0.56 -0.56 -0.71 -2.52
Consensus EPS -0.66 -0.66 -0.66 -0.66 -0.66 -0.66 -0.66 -0.56 -0.62
Estimated EPS -0.66 -0.66 -0.66 -0.66 -0.66 -0.66 -0.66 -0.56 -0.62
Number of Estimates 2 2 2 2 2 2 2 1 1
EPS Surprise $0.10 $0.10 $0.10 $0.10 $0.10 $0.10 $0.10 -$0.15 -$1.90

Stats

Summary

Market Cap:

Primary Exchange:

Website: /stocks/ftsv

Shares Outstanding:

Float:

Dividend: (%)

Beta:

Sector:

Industry:

Short Interest ():

Ethical Flags

Longest drawdown: 187 trading days

From: 2018-12-14 To: 2019-09-13

Lowest Point:

Forty Seven (FTSV) Presents At 2019 ASCO Annual Meeting - Slideshow

via: SeekingAlpha at 2019-06-04 08:17:23:000

The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more … read more...

Forty Seven (FTSV) Presents At 2019 ASCO Annual Meeting - Slideshow

via: SeekingAlpha at 2019-06-04 08:17:23:000

The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more … read more...

Forty Seven (FTSV) Presents At 2019 ASCO Annual Meeting - Slideshow

via: SeekingAlpha at 2019-06-04 08:17:23:000

The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more … read more...

Oppenheimer defends Forty Seven after 5F9-stoked plunge

via: SeekingAlpha at 2019-05-17 05:31:26:000

Oppenheimer's Mark Breidenbach says yesterday's 19% drop in Forty Seven ( FTSV ) was overdone. Shares plummeted on more than triple normal volume in response to an abstract that will be presented at the European Hematology Association Congress in Amsterdam June 13-16. More ne… read more...

Oppenheimer defends Forty Seven after 5F9-stoked plunge

via: SeekingAlpha at 2019-05-17 05:31:26:000

Oppenheimer's Mark Breidenbach says yesterday's 19% drop in Forty Seven ( FTSV ) was overdone. Shares plummeted on more than triple normal volume in response to an abstract that will be presented at the European Hematology Association Congress in Amsterdam June 13-16. More ne… read more...

Oppenheimer defends Forty Seven after 5F9-stoked plunge

via: SeekingAlpha at 2019-05-17 05:31:26:000

Oppenheimer's Mark Breidenbach says yesterday's 19% drop in Forty Seven ( FTSV ) was overdone. Shares plummeted on more than triple normal volume in response to an abstract that will be presented at the European Hematology Association Congress in Amsterdam June 13-16. More ne… read more...

Oppenheimer defends Forty Seven after 5F9-stoked plunge

via: SeekingAlpha at 2019-05-17 05:31:26:000

Oppenheimer's Mark Breidenbach says yesterday's 19% drop in Forty Seven ( FTSV ) was overdone. Shares plummeted on more than triple normal volume in response to an abstract that will be presented at the European Hematology Association Congress in Amsterdam June 13-16. More ne… read more...

Oppenheimer defends Forty Seven after 5F9-stoked plunge

via: SeekingAlpha at 2019-05-17 05:31:26:000

Oppenheimer's Mark Breidenbach says yesterday's 19% drop in Forty Seven ( FTSV ) was overdone. Shares plummeted on more than triple normal volume in response to an abstract that will be presented at the European Hematology Association Congress in Amsterdam June 13-16. More ne… read more...

Forty Seven down 10% after Q1 report

via: SeekingAlpha at 2019-05-14 08:46:44:000

Thinly traded Forty Seven ( FTSV -9.9% ) is down on average volume after posting Q1 results after the close yesterday. Since it has no product sales yet, upcoming events/catalysts merit mention. More news on: Forty Seven, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Forty Seven down 10% after Q1 report

via: SeekingAlpha at 2019-05-14 08:46:44:000

Thinly traded Forty Seven ( FTSV -9.9% ) is down on average volume after posting Q1 results after the close yesterday. Since it has no product sales yet, upcoming events/catalysts merit mention. More news on: Forty Seven, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Forty Seven down 10% after Q1 report

via: SeekingAlpha at 2019-05-14 08:46:44:000

Thinly traded Forty Seven ( FTSV -9.9% ) is down on average volume after posting Q1 results after the close yesterday. Since it has no product sales yet, upcoming events/catalysts merit mention. More news on: Forty Seven, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Forty Seven's (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-13 16:36:21:000

Forty Seven, Inc. (FTSV) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Hannah Deresiewicz Stern Investor Relations Mark McCamish Chief Executive Officer Chris Takimoto Chief Medical Officer Ann Rhoads Chief Fin… read more...

Forty Seven's (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-13 16:36:21:000

Forty Seven, Inc. (FTSV) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Hannah Deresiewicz Stern Investor Relations Mark McCamish Chief Executive Officer Chris Takimoto Chief Medical Officer Ann Rhoads Chief Fin… read more...

Forty Seven's (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-13 16:36:21:000

Forty Seven, Inc. (FTSV) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Hannah Deresiewicz Stern Investor Relations Mark McCamish Chief Executive Officer Chris Takimoto Chief Medical Officer Ann Rhoads Chief Fin… read more...

Forty Seven misses by $0.08

via: SeekingAlpha at 2019-05-13 12:04:05:000

Forty Seven (NASDAQ: FTSV ): Q1 GAAP EPS of -$0.74 misses by $0.08 . More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Forty Seven, Inc.'s (FTSV) CEO Mark McCamish on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-28 16:50:56:000

Forty Seven, Inc. (FTSV) Q4 2018 Results Earnings Conference Call March 28, 2019, 04:30 AM ET Company Participants Hannah Deresiewicz - Investor Relations Mark McCamish - President and Chief Executive Officer Ann Rhoads - Chief Financial Officer Chris Takimoto - Chief Medical O… read more...

Forty Seven, Inc.'s (FTSV) CEO Mark McCamish on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-28 16:50:56:000

Forty Seven, Inc. (FTSV) Q4 2018 Results Earnings Conference Call March 28, 2019, 04:30 AM ET Company Participants Hannah Deresiewicz - Investor Relations Mark McCamish - President and Chief Executive Officer Ann Rhoads - Chief Financial Officer Chris Takimoto - Chief Medical O… read more...

Forty Seven, Inc.'s (FTSV) CEO Mark McCamish on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-28 16:50:56:000

Forty Seven, Inc. (FTSV) Q4 2018 Results Earnings Conference Call March 28, 2019, 04:30 AM ET Company Participants Hannah Deresiewicz - Investor Relations Mark McCamish - President and Chief Executive Officer Ann Rhoads - Chief Financial Officer Chris Takimoto - Chief Medical O… read more...

Forty Seven, Inc.'s (FTSV) CEO Mark McCamish on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-28 16:50:56:000

Forty Seven, Inc. (FTSV) Q4 2018 Results Earnings Conference Call March 28, 2019, 04:30 AM ET Company Participants Hannah Deresiewicz - Investor Relations Mark McCamish - President and Chief Executive Officer Ann Rhoads - Chief Financial Officer Chris Takimoto - Chief Medical O… read more...

Forty Seven, Inc.'s (FTSV) CEO Mark McCamish on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-28 16:50:56:000

Forty Seven, Inc. (FTSV) Q4 2018 Results Earnings Conference Call March 28, 2019, 04:30 AM ET Company Participants Hannah Deresiewicz - Investor Relations Mark McCamish - President and Chief Executive Officer Ann Rhoads - Chief Financial Officer Chris Takimoto - Chief Medical O… read more...

Forty Seven beats by $0.09

via: SeekingAlpha at 2019-03-28 12:07:29:000

Forty Seven (NASDAQ: FTSV ): Q4 GAAP EPS of -$0.56 beats by $0.09 . More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Apple Makes Its Video-Streaming Move (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-03-24 04:10:31:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Apple Makes Its Video-Streaming Move (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-03-24 04:10:31:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Apple Makes Its Video-Streaming Move (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-03-24 04:10:31:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Apple Makes Its Video-Streaming Move

via: SeekingAlpha at 2019-03-23 05:05:44:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The increasingly hot market for online video delivery is set to take another sharp … read more...

Forty Seven (FTSV) Investor Presentation - Slideshow

via: SeekingAlpha at 2019-03-19 09:44:22:000

The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more … read more...

Forty Seven (FTSV) Investor Presentation - Slideshow

via: SeekingAlpha at 2019-03-19 09:44:22:000

The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more … read more...

Forty Seven (FTSV) Investor Presentation - Slideshow

via: SeekingAlpha at 2019-03-19 09:44:22:000

The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more … read more...

March Outlook For Forty Seven Inc.

via: SeekingAlpha at 2019-03-11 14:23:29:000

Forty Seven ( FTSV ) made a solid bullish movement as predicted in our last analysis piece for this stock, as it broke above the bullish pennant to hit a high of just under $24 in December 2018. The price has since cooled off from that point, retreating to about $13 before resuming a climb… read more...

March Outlook For Forty Seven Inc.

via: SeekingAlpha at 2019-03-11 14:23:29:000

Forty Seven ( FTSV ) made a solid bullish movement as predicted in our last analysis piece for this stock, as it broke above the bullish pennant to hit a high of just under $24 in December 2018. The price has since cooled off from that point, retreating to about $13 before resuming a climb… read more...

March Outlook For Forty Seven Inc.

via: SeekingAlpha at 2019-03-11 14:23:29:000

Forty Seven ( FTSV ) made a solid bullish movement as predicted in our last analysis piece for this stock, as it broke above the bullish pennant to hit a high of just under $24 in December 2018. The price has since cooled off from that point, retreating to about $13 before resuming a climb… read more...

Earnings Heat Check (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-01-20 07:35:01:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, loo… read more...

Earnings Heat Check (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-01-20 07:35:01:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, loo… read more...

Earnings Heat Check (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-01-20 07:35:01:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, loo… read more...

Earnings Heat Check (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-01-20 07:35:01:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, loo… read more...

Stocks To Watch: Earnings Heat Check

via: SeekingAlpha at 2019-01-19 08:20:44:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season really starts to heat up after major banks knocked out some solid r… read more...

Microcaps mostly among midday movers

via: SeekingAlpha at 2018-12-19 12:42:09:000

Gainers: Marin Software (NASDAQ: MRIN ) +55% . Adial Pharmaceuticals (NASDAQ: ADIL ) +22% . Internap (NASDAQ: INAP ) +19% . ABM Industries Incorporated (NYSE: ABM ) +18% . AutoWeb (NASDAQ: AUTO ) +18% . Limbach Holdings (NASDAQ: LMB ) +17% . Winnebago Industries (NYSE: WGO ) +… read more...

Microcaps mostly among midday movers

via: SeekingAlpha at 2018-12-19 12:42:09:000

Gainers: Marin Software (NASDAQ: MRIN ) +55% . Adial Pharmaceuticals (NASDAQ: ADIL ) +22% . Internap (NASDAQ: INAP ) +19% . ABM Industries Incorporated (NYSE: ABM ) +18% . AutoWeb (NASDAQ: AUTO ) +18% . Limbach Holdings (NASDAQ: LMB ) +17% . Winnebago Industries (NYSE: WGO ) +… read more...

Microcaps mostly among midday movers

via: SeekingAlpha at 2018-12-19 12:42:09:000

Gainers: Marin Software (NASDAQ: MRIN ) +55% . Adial Pharmaceuticals (NASDAQ: ADIL ) +22% . Internap (NASDAQ: INAP ) +19% . ABM Industries Incorporated (NYSE: ABM ) +18% . AutoWeb (NASDAQ: AUTO ) +18% . Limbach Holdings (NASDAQ: LMB ) +17% . Winnebago Industries (NYSE: WGO ) +… read more...

Long-Term Outlook For Forty Seven Inc.

via: SeekingAlpha at 2018-12-17 06:00:25:000

Forty Seven Inc. ( FTSV ) is involved in the development of immune-mediated drug treatments for cancer. It is a relatively new company and therefore does not have significant price history on the charts. Without many references to support and resistance price levels, analysis of such stocks ca… read more...

Long-Term Outlook For Forty Seven Inc.

via: SeekingAlpha at 2018-12-17 06:00:25:000

Forty Seven Inc. ( FTSV ) is involved in the development of immune-mediated drug treatments for cancer. It is a relatively new company and therefore does not have significant price history on the charts. Without many references to support and resistance price levels, analysis of such stocks ca… read more...

XPO, SRC, LLNW and TLRD among notable midday movers

via: SeekingAlpha at 2018-12-13 12:43:03:000

Gainers: Spirit Realty Capital (NYSE: SRC ) +421% . Adial Pharmaceuticals (NASDAQ: ADIL ) +63% . Yulong Eco-Materials Limited (NASDAQ: YECO ) +26% . Qudian (NYSE: QD ) +25% . Kezar Life Sciences (NASDAQ: KZR ) +21% . Qutoutiao (NASDAQ: QTT ) +17% . Marin Software (NASDAQ: MRIN … read more...

XPO, SRC, LLNW and TLRD among notable midday movers

via: SeekingAlpha at 2018-12-13 12:43:03:000

Gainers: Spirit Realty Capital (NYSE: SRC ) +421% . Adial Pharmaceuticals (NASDAQ: ADIL ) +63% . Yulong Eco-Materials Limited (NASDAQ: YECO ) +26% . Qudian (NYSE: QD ) +25% . Kezar Life Sciences (NASDAQ: KZR ) +21% . Qutoutiao (NASDAQ: QTT ) +17% . Marin Software (NASDAQ: MRIN … read more...

XPO, SRC, LLNW and TLRD among notable midday movers

via: SeekingAlpha at 2018-12-13 12:43:03:000

Gainers: Spirit Realty Capital (NYSE: SRC ) +421% . Adial Pharmaceuticals (NASDAQ: ADIL ) +63% . Yulong Eco-Materials Limited (NASDAQ: YECO ) +26% . Qudian (NYSE: QD ) +25% . Kezar Life Sciences (NASDAQ: KZR ) +21% . Qutoutiao (NASDAQ: QTT ) +17% . Marin Software (NASDAQ: MRIN … read more...

Investment Thesis Of Forty Seven

via: SeekingAlpha at 2018-10-11 12:37:40:000

C ompany overview Forty Seven, Inc. ( FTSV ) is a clinical stage biotech company headquartered in Menlo Park, CA. This company completed its IPO in June 2018 by raising $116 million with price of $16.00 per share. The company is focusing on immune-therapy field by developing novel che… read more...

Investment Thesis Of Forty Seven

via: SeekingAlpha at 2018-10-11 12:37:40:000

C ompany overview Forty Seven, Inc. ( FTSV ) is a clinical stage biotech company headquartered in Menlo Park, CA. This company completed its IPO in June 2018 by raising $116 million with price of $16.00 per share. The company is focusing on immune-therapy field by developing novel che… read more...

Investment Thesis Of Forty Seven

via: SeekingAlpha at 2018-10-11 12:37:40:000

C ompany overview Forty Seven, Inc. ( FTSV ) is a clinical stage biotech company headquartered in Menlo Park, CA. This company completed its IPO in June 2018 by raising $116 million with price of $16.00 per share. The company is focusing on immune-therapy field by developing novel che… read more...

Trillium Therapeutics Updates On Lead Lymphoma Trials

via: SeekingAlpha at 2018-10-04 18:51:27:000

Trillium Therapeutics ( TRIL ) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here . Last week, Trill… read more...

Trillium Therapeutics Updates On Lead Lymphoma Trials

via: SeekingAlpha at 2018-10-04 18:51:27:000

Trillium Therapeutics ( TRIL ) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here . Last week, Trill… read more...

Trillium Therapeutics Updates On Lead Lymphoma Trials

via: SeekingAlpha at 2018-10-04 18:51:27:000

Trillium Therapeutics ( TRIL ) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here . Last week, Trill… read more...

Daily Insider Ratings Round Up 8/24/18

via: SeekingAlpha at 2018-08-28 13:32:31:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signif… read more...

Daily Insider Ratings Round Up 8/24/18

via: SeekingAlpha at 2018-08-28 13:32:31:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signif… read more...

Daily Insider Ratings Round Up 8/24/18

via: SeekingAlpha at 2018-08-28 13:32:31:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signif… read more...

Daily Insider Ratings Round Up 8/20/18

via: SeekingAlpha at 2018-08-22 15:46:56:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 8/20/18

via: SeekingAlpha at 2018-08-22 15:46:56:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 8/20/18

via: SeekingAlpha at 2018-08-22 15:46:56:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Forty Seven reports Q2 results

via: SeekingAlpha at 2018-08-13 16:32:08:000

Forty Seven (NASDAQ: FTSV ): Q2 EPS of -$2.52 More news on: Forty Seven, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Forty Seven reports Q2 results

via: SeekingAlpha at 2018-08-13 16:32:08:000

Forty Seven (NASDAQ: FTSV ): Q2 EPS of -$2.52 More news on: Forty Seven, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Forty Seven reports Q2 results

via: SeekingAlpha at 2018-08-13 16:32:08:000

Forty Seven (NASDAQ: FTSV ): Q2 EPS of -$2.52 More news on: Forty Seven, Earnings news and commentary, Healthcare stocks news, Read more … read more...

47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit

via: SeekingAlpha at 2018-08-01 16:46:42:000

CD47, a novel immune checkpoint in the innate immune system, is a rapidly emerging target in cancer immunotherapy. Previously, I spoke to the merits of the technology and the key drivers fueling a cohort of 8 companies developing CD47-directed therapies. Today, I provide updated commentary o… read more...

47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit

via: SeekingAlpha at 2018-08-01 16:46:42:000

CD47, a novel immune checkpoint in the innate immune system, is a rapidly emerging target in cancer immunotherapy. Previously, I spoke to the merits of the technology and the key drivers fueling a cohort of 8 companies developing CD47-directed therapies. Today, I provide updated commentary o… read more...

47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit

via: SeekingAlpha at 2018-08-01 16:46:42:000

CD47, a novel immune checkpoint in the innate immune system, is a rapidly emerging target in cancer immunotherapy. Previously, I spoke to the merits of the technology and the key drivers fueling a cohort of 8 companies developing CD47-directed therapies. Today, I provide updated commentary o… read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Stocks To Watch: FANGs Out In Tech

via: SeekingAlpha at 2018-07-21 08:59:33:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There's no hiding this week if you're an investor in the tech sector, with heavywei… read more...

Company Spotlight: Trillium Therapeutics

via: SeekingAlpha at 2018-07-18 10:18:33:000

Previously, I reported a summary of the field of immunotherapies targeting CD47, including a description of the scientific background and an overview of the potential impacts for patients. I also provided a spotlight of Forty Seven , one of the leading firms in the field. Today I report … read more...

Company Spotlight: Trillium Therapeutics

via: SeekingAlpha at 2018-07-18 10:18:33:000

Previously, I reported a summary of the field of immunotherapies targeting CD47, including a description of the scientific background and an overview of the potential impacts for patients. I also provided a spotlight of Forty Seven , one of the leading firms in the field. Today I report … read more...

Company Spotlight: Trillium Therapeutics

via: SeekingAlpha at 2018-07-18 10:18:33:000

Previously, I reported a summary of the field of immunotherapies targeting CD47, including a description of the scientific background and an overview of the potential impacts for patients. I also provided a spotlight of Forty Seven , one of the leading firms in the field. Today I report … read more...

Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

via: SeekingAlpha at 2018-07-12 05:47:18:000

Obviously if you want to get good at something which is competitive, you have to think about it and practice a lot. You have to keep learning because the world keeps changing and competitors keep learning. You have to go to bed wiser than you got up. People who do that almost never fail utter… read more...

Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

via: SeekingAlpha at 2018-07-12 05:47:18:000

Obviously if you want to get good at something which is competitive, you have to think about it and practice a lot. You have to keep learning because the world keeps changing and competitors keep learning. You have to go to bed wiser than you got up. People who do that almost never fail utter… read more...

Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

via: SeekingAlpha at 2018-07-12 05:47:18:000

Obviously if you want to get good at something which is competitive, you have to think about it and practice a lot. You have to keep learning because the world keeps changing and competitors keep learning. You have to go to bed wiser than you got up. People who do that almost never fail utter… read more...

Company Spotlight: Forty Seven

via: SeekingAlpha at 2018-07-11 08:15:18:000

Previously, I reviewed industry efforts to commercialize therapies targeting the CD47/SIRPa pathway. In the first part of a series intended to profile the companies in this space, I present a company profile for Forty Seven (FTSV). Please reference my original article linked to above for mor… read more...

Your Daily Pharma Scoop IPO Review: AUTL Zooms, STIM Surges, FTSV Slips

via: SeekingAlpha at 2018-07-09 08:59:17:000

After the last instalment of our discussion of the IPOs for the week ending June 22, six more biotech IPOs were launched. However, usually the IPO market cools down in the run up to the July 4 holiday week and afterwards. This week may therefore seem to be a little dull compared to the earlier… read more...

Your Daily Pharma Scoop IPO Review: AUTL Zooms, STIM Surges, FTSV Slips

via: SeekingAlpha at 2018-07-09 08:59:17:000

After the last instalment of our discussion of the IPOs for the week ending June 22, six more biotech IPOs were launched. However, usually the IPO market cools down in the run up to the July 4 holiday week and afterwards. This week may therefore seem to be a little dull compared to the earlier… read more...

Targeting CD47: To Eat Or Not To Eat?

via: SeekingAlpha at 2018-07-03 12:00:25:000

Scientific rationale supports novel approach targeting of innate immune system CD47, often called the Dont Eat Me protein, is an immune checkpoint that binds to the SIRPa receptor on macrophages, inhibiting phagocytosis. CD47 is overexpressed in several types of can… read more...

Targeting CD47: To Eat Or Not To Eat?

via: SeekingAlpha at 2018-07-03 12:00:25:000

Scientific rationale supports novel approach targeting of innate immune system CD47, often called the Dont Eat Me protein, is an immune checkpoint that binds to the SIRPa receptor on macrophages, inhibiting phagocytosis. CD47 is overexpressed in several types of can… read more...

Targeting CD47: To Eat Or Not To Eat?

via: SeekingAlpha at 2018-07-03 12:00:25:000

Scientific rationale supports novel approach targeting of innate immune system CD47, often called the Dont Eat Me protein, is an immune checkpoint that binds to the SIRPa receptor on macrophages, inhibiting phagocytosis. CD47 is overexpressed in several types of can… read more...

Targeting CD47: To Eat Or Not To Eat?

via: SeekingAlpha at 2018-07-03 12:00:25:000

Scientific rationale supports novel approach targeting of innate immune system CD47, often called the Dont Eat Me protein, is an immune checkpoint that binds to the SIRPa receptor on macrophages, inhibiting phagocytosis. CD47 is overexpressed in several types of can… read more...

U.S. IPO Weekly Recap: 12 IPOs Price In Record-Setting Week, Month And Quarter

via: SeekingAlpha at 2018-06-30 09:59:49:000

12 IPOs raised $2.3 billion in the IPO market's busiest week of the year. June 2018 also set a record as the most active month for IPOs in three years . And as IPO Pro subscribers can see in our newly-released Second Quarter IPO Review : the 2Q18 saw more IPOs than any quarter in three ye… read more...

U.S. IPO Weekly Recap: 12 IPOs Price In Record-Setting Week, Month And Quarter

via: SeekingAlpha at 2018-06-30 09:59:49:000

12 IPOs raised $2.3 billion in the IPO market's busiest week of the year. June 2018 also set a record as the most active month for IPOs in three years . And as IPO Pro subscribers can see in our newly-released Second Quarter IPO Review : the 2Q18 saw more IPOs than any quarter in three ye… read more...

U.S. IPO Weekly Recap: 12 IPOs Price In Record-Setting Week, Month And Quarter

via: SeekingAlpha at 2018-06-30 09:59:49:000

12 IPOs raised $2.3 billion in the IPO market's busiest week of the year. June 2018 also set a record as the most active month for IPOs in three years . And as IPO Pro subscribers can see in our newly-released Second Quarter IPO Review : the 2Q18 saw more IPOs than any quarter in three ye… read more...

Forty Seven prices initial public offering

via: SeekingAlpha at 2018-06-28 05:55:06:000

Forty Seven (NASDAQ: FTSV ) priced its initial public offering of 7.035M shares of common stock at a price to the public of $16.00 per share. More news on: Forty Seven, Read more … read more...

Forty Seven prices initial public offering

via: SeekingAlpha at 2018-06-28 05:55:06:000

Forty Seven (NASDAQ: FTSV ) priced its initial public offering of 7.035M shares of common stock at a price to the public of $16.00 per share. More news on: Forty Seven, Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud